imipramine has been researched along with aripiprazole in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Bienkowski, P; Bucki, A; Jastrzębska-Więsek, M; Kazek, G; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Siwek, A; Śniecikowska, J; Wasik, A; Wesołowska, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bucki, A; Gryboś, A; Głuch-Lutwin, M; Jastrzębska-Więsek, M; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Pytka, K; Siwek, A; Śniecikowska, J; Wesołowska, A; Więckowski, K | 1 |
| Handzlik, J; Jastrzębska-Więsek, M; Kieć-Kononowicz, K; Kucwaj-Brysz, K; Latacz, G; Lubelska, A; Partyka, A; Wesołowska, A | 1 |
| Fraile, S; García, B; Hidalgo, FJ; Lopez, E | 1 |
| Adham, N; Gruca, P; Gyertyán, I; Kiss, B; Lasoń-Tyburkiewicz, M; Papp, M | 1 |
| Adham, N; Banasr, M; Duman, RS; Duric, V; Franklin, T; Gyertyán, I; Kiss, B; Lepack, A | 1 |
1 review(s) available for imipramine and aripiprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for imipramine and aripiprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indoles; Ligands; Male; Models, Molecular; Molecular Structure; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Swimming | 2015 |
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
Topics: Affect; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Dementia; Dopamine Agonists; Drug Design; Humans; Indoles; Ligands; Models, Molecular; Pyridines; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists | 2017 |
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
Topics: Dose-Response Relationship, Drug; Humans; Hydantoins; Molecular Structure; Piperazines; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 2018 |
[Possible malignant neuroleptic syndrome associated with aripiprazole and imipramine and treated with bromocriptine].
Topics: Antipsychotic Agents; Aripiprazole; Bromocriptine; Combined Modality Therapy; Drug Therapy, Combination; Emergencies; Frontotemporal Dementia; Humans; Imipramine; Lorazepam; Male; Mental Disorders; Middle Aged; Neuroleptic Malignant Syndrome; Oxygen Inhalation Therapy; Piperazines; Quinolones; Respiration, Artificial; Respiratory Insufficiency | 2013 |
Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Dietary Sucrose; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Imipramine; Male; Piperazines; Quinolones; Rats, Wistar; Stress, Psychological | 2014 |
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
Topics: Anhedonia; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Aripiprazole; Chronic Disease; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Imipramine; Male; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Receptors, Dopamine D3; Stress, Psychological; Uncertainty | 2017 |